IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies

Pablo Domizi(Institute for Stem Cell Biology and Regenerative Medicine), Kara L. Davis(Stanford Medicine), Milton Merchant(Institute for Stem Cell Biology and Regenerative Medicine), Nirali N. Shah(National Institutes of Health), Robbie G. Majzner(Dana-Farber Cancer Institute), Bonnie Yates(National Institutes of Health), Astraea Jager(Institute for Stem Cell Biology and Regenerative Medicine), Kaithlen Zen B Pacheco(Stanford University), Sean C. Bendall(Stanford University), Reema Baskar(Stanford University), Allison Barz Leahy(Memorial Sloan Kettering Cancer Center), Charles G. Mullighan(St. Jude Children's Research Hospital), Crystal L. Mackall(Stanford University), Warren D. Reynolds(Stanford University), Bita Sahaf(Stanford University), Elena Sotillo(Stanford University), Brian J. Sworder(City Of Hope National Medical Center), Maria Caterina Rotiroti(Dana-Farber Cancer Institute), Sean A. Yamada‐Hunter(Stanford University), David M. Barrett(University of Montana), Stephan A. Grupp(Children's Hospital of Philadelphia), Regina M. Myers(Children's Hospital of Philadelphia), Hao‐Wei Wang(Fu Jen Catholic University), Jolanda Sarno(Institute for Stem Cell Biology and Regenerative Medicine), Yuxuan Liu(Nanchang University), Ash A. Alizadeh(California Institute for Regenerative Medicine)
Nature Communications
April 23, 2025
Cited by 18


Related Papers